BR0100946A - Metabólitos de hexahidropirazolo[4,3-c] piridina - Google Patents

Metabólitos de hexahidropirazolo[4,3-c] piridina

Info

Publication number
BR0100946A
BR0100946A BR0100946-0A BR0100946A BR0100946A BR 0100946 A BR0100946 A BR 0100946A BR 0100946 A BR0100946 A BR 0100946A BR 0100946 A BR0100946 A BR 0100946A
Authority
BR
Brazil
Prior art keywords
metabolites
oxo
benzyl
racemic
pharmaceutically acceptable
Prior art date
Application number
BR0100946-0A
Other languages
English (en)
Inventor
Siamak Cyrus Khojasteh-Bakht
John Paul O Donnell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0100946A publication Critical patent/BR0100946A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: "METABóLITOS DEHEXAHIDROPIRAZOLO[4,3C] PIRIDINA". A invençãoproporciona metabólitos do composto2-amino-N-[2(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pirazolo-[4,3-c] piridin-5il)-1-(R)-benzil-oximetil-2-oxo-etil]-isobutiramida, asmisturas racêmicasdiastereoméricas e isómeros ópticos destes, assuas pró-drogas e os sais farmaceuticamente aceitáveis dosmetabólitos, misturas racêmicasdiastereoméricas, isómeros ópticose pró-drogas; composições farmacêuticas destes; e métodos deutilizar os metabólitos e as formulações no tratamento de doençasrelacionadas com níveis reduzidos do hormónio do crescimento. Ainvenção proporciona ainda um kit compreendendo um metabólitodo composto2-amino-N-[2-(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7hexahidro-pirazolo-[4,3-c]piridin-5-il)-1 -(R)-benzil-oximetil-2-oxo-etíl]-isobutiramida,uma mistura racêmica-diastereomérica ou um isómero óptico deste,uma sua pró-droga ou um sal farmaceuticamente aceitável dometabólito, mistura racómica-diastereamérica, isómero óptico oupró-droga e um excipiente, veículo ou diluente farmaceuticamenteaceitável em uma primeira forma de dosagem; estrogênio,progesterona Premarin<32>, ou um bisfosfonato, preferencialmentealendronato, e um excipiente, veículo ou diluentefarmaceuticamente aceitável em uma segunda forma de dosagem;e uma embalagem.
BR0100946-0A 2000-03-09 2001-03-09 Metabólitos de hexahidropirazolo[4,3-c] piridina BR0100946A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18796500P 2000-03-09 2000-03-09

Publications (1)

Publication Number Publication Date
BR0100946A true BR0100946A (pt) 2001-10-30

Family

ID=22691219

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0100946-0A BR0100946A (pt) 2000-03-09 2001-03-09 Metabólitos de hexahidropirazolo[4,3-c] piridina

Country Status (5)

Country Link
US (1) US6531449B2 (pt)
EP (1) EP1132388A3 (pt)
JP (1) JP3529736B2 (pt)
BR (1) BR0100946A (pt)
CA (1) CA2339528C (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165816A1 (en) * 2001-05-02 2002-11-07 Barz Graydon Lee Method for stochastically modeling electricity prices
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
EP1907066A4 (en) * 2005-07-22 2009-10-21 Tomotherapy Inc SYSTEM AND METHOD FOR THE ADMINISTRATION OF RADIATION THERAPY IN A POTENTIAL INTEREST
US7639854B2 (en) * 2005-07-22 2009-12-29 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
EP1906827A4 (en) * 2005-07-22 2009-10-21 Tomotherapy Inc SYSTEM AND METHOD FOR EVALUATING THE DOSE USED BY A RADIATION THERAPY SYSTEM
JP2009502257A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド デリバーされた線量を評価するための方法およびシステム
EP1907968A4 (en) 2005-07-22 2009-10-21 Tomotherapy Inc METHOD AND SYSTEM FOR EVALUATING QUALITY ASSURANCE CRITERIA FOR A TREATMENT ADMINISTRATION PROGRAM
ATE507879T1 (de) * 2005-07-22 2011-05-15 Tomotherapy Inc System zur verabreichung einer strahlentherapie auf ein sich bewegendes zielgebiet
US7574251B2 (en) * 2005-07-22 2009-08-11 Tomotherapy Incorporated Method and system for adapting a radiation therapy treatment plan based on a biological model
JP2009507524A (ja) * 2005-07-22 2009-02-26 トモセラピー・インコーポレーテッド 変形マップに制約を課す方法およびそれを実装するためのシステム
US20070195922A1 (en) * 2005-07-22 2007-08-23 Mackie Thomas R System and method of monitoring the operation of a medical device
AU2006272821A1 (en) 2005-07-23 2007-02-01 Tomotherapy Incorporated Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
CN105027227B (zh) 2013-02-26 2017-09-08 安科锐公司 电磁致动的多叶准直器
WO2015053023A1 (ja) * 2013-10-08 2015-04-16 シャープ株式会社 画像表示装置
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) * 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues

Also Published As

Publication number Publication date
CA2339528C (en) 2007-05-08
JP2001278866A (ja) 2001-10-10
EP1132388A2 (en) 2001-09-12
US20020002138A1 (en) 2002-01-03
JP3529736B2 (ja) 2004-05-24
US6531449B2 (en) 2003-03-11
CA2339528A1 (en) 2001-09-09
EP1132388A3 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
BR0100946A (pt) Metabólitos de hexahidropirazolo[4,3-c] piridina
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
IL178745A (en) Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
WO2005102381A1 (ja) カテプシンｋ阻害薬およびpth類を併用することを特徴とする骨密度増加剤
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
SV2002000440A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb
CA2360313A1 (en) Glucocorticoid receptor modulators
YU37203A (sh) Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti
CA2442478A1 (en) Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
CA2360308A1 (en) Glucocorticoid receptor modulators
WO2005002582A3 (en) Trp-p8 active compounds and therapeutic treatment methods
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
ES2271229T3 (es) Uso de antagonistas mglur5 para el tratamiento de condiciones pruriticas.
JP6377620B2 (ja) グルコース取り込みを改善するための組成物および方法
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
KR20030027007A (ko) 엔도텔린 길항제를 사용하여 암 및 이와 관련된 통증을치료하는 방법
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.